An overarching study for children and adults with frontline and relapsed rhabdomyosarcoma
Age: Children, teenagers and adults (age criteria depends on which treatment you receive)
Phase: 1/2
This study will assess several treatment therapies, looking at survival and long term side effects of treatment in children, teenagers and adults with newly diagnosed or recurrent rhabdomyosarcoma. It will explore whether outcomes can be improved by looking at the most effective use of radiotherapy and maintenance chemotherapy, and by the introduction of new treatment combinations in frontline chemotherapy.
More information can be found at clinicaltrials.gov
To find out more about this trial and whether you could take part, talk to your clinical team.
Locations:
- Aberdeen – Royal Aberdeen Children’s Hospital
- Belfast – Belfast City Hospital, Royal Belfast Hospital for Sick Children
- Birmingham – Birmingham Children’s Hospital, The Queen Elizabeth Hospital
- Bristol – Bristol Haematology and Oncology Centre, British Royal Hospital for Children
- Cambridge – Addenbrooke’s Hospital
- Cardiff – Noah’s Ark Children’s Hospital for Wales, Velindre Hospital
- Edinburgh – Royal Hospital for Children and Young People
- Glasgow – Beatson West of Scotland Cancer Centre, Royal Hospital for Children Glasgow
- Leeds – Leeds General Infirmary, St James’s University Hospital
- Leicester – Leicester Royal Infirmary
- Liverpool – Alder Hey Children’s Hospital
- London – Royal Marsden Hospital, University College London Hospital, Great Ormond Street Hospital for Children
- Manchester – Royal Manchester Children’s Hospital, Christie Hospital
- Newcastle upon Tyne – Royal Victoria Infirmary
- Nottingham – Nottingham City Hospital, Queen’s Medical Centre
- Oxford – John Radcliffe Hospital
- Sheffield – Sheffield Children’s Hospital, Weston Park Hospital
- Southampton – Southampton General Hospital
- Sutton – Royal Marsden Hospital
- Wirral – Clatterbridge Cancer Centre
